Trial Profile
An open label, non-randomized phase I/II study of ramucirumab in combination with nab-paclitaxel as second-line therapy in patients with advanced gastric cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jul 2019
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Paclitaxel
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2019 Status changed from recruiting to discontinued.
- 23 May 2016 New trial record